Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AAA

Ratings ESG MSCI

Ratings Novartis AG: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: Novartis AG
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Novartis AG
  • The company's enterprise value to sales, at 4.57 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Rating Financials

Novartis AG SectorSwitzerland

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Novartis AG SectorSwitzerland

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Novartis AG SectorSwitzerland

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Novartis AG SectorSwitzerland

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Novartis AG SectorSwitzerland

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
297B
AAA
893B
A
586B
BBB
403B
AA
338B
AA
301B
A
287B
A
204B
A
181B
AAA
172B
A
Average 366.1B
AA
Weighted average by Cap.
AA
SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW